NASDAQ$URGN
UroGen Pharma Ltd · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
UroGen reported positive momentum and reaffirmed 2022 full-year revenue guidance.
UroGen Pharma reported a net product revenue of $16.6 million for Q2 2022, a 28% increase year-over-year. The company is on track with its clinical development programs, including the UGN-102 Phase 3 trial and UGN-301 Phase 1 clinical trial. They are focused on reaching cash flow break-even in 2025 while strategically deploying capital.
- Jelmyto net product revenue reached $16.6 million, a 22% increase from the previous quarter and a 28% increase year-over-year.
- The company reaffirmed its 2022 full-year revenue guidance of $70-$80 million.
- Enrollment is ongoing and on track for the UGN-102 Phase 3 ENVISION pivotal trial, with completion anticipated by the end of 2022.
- Progress was made in the first-in-human multi-arm Phase 1 clinical trial of UGN-301 in high-grade non-muscle invasive bladder cancer (HG-NMIBC).
Headline financials
Revenue & EPS history
UroGen · Revenue · Quarterly
$16.6M
Revenue by segment
UroGen · $16.6M total across 1 segment · Q2 2022
- JELMYTO$16.6M+27.4%100.0%
Forward guidance
UroGen anticipates full year 2022 net product revenues from Jelmyto to be in the range of $70 to $80 million. Anticipated full year 2022 operating expenses to be in the range of $130 to $140 million. Anticipates full year 2022 non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $22 to $26 million, of which approximately $9.1 to $10.4 million will be paid in cash.
Tailwinds
- Reiterated full year 2022 net product revenues from Jelmyto to be in the range of $70 to $80 million.
- Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial is on track to be completed before end of 2022.
- Progressed first in human multi-arm Phase 1 clinical trial of UGN-301.
- Jelmyto adoption continues to grow.
- Focus on reaching cash flow break-even in 2025.
Headwinds
- Clinical trial enrollment challenges may impact the expected timing of ongoing and planned clinical trials.
- Potential safety and other complications from any approved products.
- The company may face challenges in commercialization activities, including complications resulting from the ongoing COVID-19 pandemic.
- The ability to satisfy required customary bring down conditions and deliverables for the second tranche of the term loan facility with Pharmakon is uncertain.
- Negative effects on UroGen’s business, commercialization and product development plans caused by or associated with COVID-19 or geopolitical events.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.5%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-4.5%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+22.0%
Q3 2025
Best reaction
-28.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.2% | +31.3% | +12.6% | |
| Q4 2025 | -12.4% | -5.7% | -12.7% | |
| Q3 2025 | +22.0% | +22.4% | +19.0% | |
| Q1 2025 | +7.1% | -29.6% | -29.7% | |
| Q4 2024 | +1.0% | +12.7% | +2.9% | |
| Q3 2024 | -0.9% | +4.8% | +0.7% | |
| Q2 2024 | +3.0% | +2.0% | -10.1% | |
| Q1 2024 | +1.8% | +3.8% | -0.2% | |
| Q4 2023 | -17.2% | -14.0% | -13.6% | |
| Q3 2023 | -1.5% | +6.0% | +29.6% | |
| Q2 2023 | +7.1% | +8.0% | -20.0% | |
| Q1 2023 | +4.8% | +2.2% | +1.3% | |
| Q4 2022 | -11.7% | -9.1% | +0.0% | |
| Q3 2022 | -18.8% | -17.2% | -27.6% | |
| Q2 2022 | -4.3% | -5.5% | -11.4% | |
| Q1 2022 | -2.7% | -4.0% | +13.1% | |
| Q4 2021 | -1.9% | -4.4% | -17.3% | |
| Q3 2021 | -28.7% | -37.0% | -46.9% | |
| Q2 2021 | -1.1% | -1.8% | +14.1% | |
| Q1 2021 | -16.3% | -2.9% | -4.7% | |
| Q4 2020 | +2.4% | -0.3% | -5.9% | |
| Q3 2020 | +0.3% | -1.9% | -22.8% | |
| Q2 2020 | +4.4% | -0.9% | -7.7% | |
| Q1 2020 | -0.2% | +2.8% | +13.4% | |
| Q4 2019 | +6.8% | +6.8% | -39.5% | |
| Q3 2019 | +8.0% | +9.7% | +37.9% | |
| Q2 2019 | -1.2% | -0.7% | +2.2% | |
| Q1 2019 | +3.6% | +1.9% | -1.7% | |
| Q4 2018 | +4.1% | +3.3% | -3.8% | |
| Q3 2018 | +0.7% | +1.0% | -0.3% | |
| Q2 2018 | -10.0% | -7.1% | -3.7% | |
| Q1 2018 | +1.8% | +6.0% | -9.9% | |
| Q4 2017 | -5.8% | -7.5% | +3.0% | |
| Q3 2017 | -3.9% | -5.2% | -14.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro